GlassScriptPhysician profile
Subhash C Gumber
NPI 1205975398
$130,463.99
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,807 · 2020: $1,656 · 2021: $1,322 · 2022: $53K · 2023: $73K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Travel and Lodging: $15K · Food and Beverage: $1,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,028.00 |
| Travel and Lodging | $14,953.81 |
| Food and Beverage | $1,722.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $102,487.84 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $21,470.38 | 2022-2023 | Dupixent |
| Abbvie INC. | $1,738.30 | 2019-2023 | |
| Micro-Tech Endoscopy USA, INC. | $900.00 | 2020 | |
| Pfizer INC. | $609.89 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $542.31 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $485.34 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $361.94 | 2021-2022 | |
| Janssen Biotech, INC. | $278.56 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $212.26 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $173.73 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $173.17 | 2021-2022 | |
| Gilead Sciences, INC. | $158.56 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $123.56 | 2019 | |
| Ferring Pharmaceuticals INC. | $107.53 | 2019-2023 | Cimzia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $106.86 | 2019-2021 | |
| Celgene Corporation | $105.47 | 2021-2022 | |
| Ucb, INC. | $66.96 | 2019 | |
| Merck Sharp & Dohme LLC | $61.15 | 2019-2022 | |
| Braintree Laboratories, INC. | $49.77 | 2019-2021 | |
| Redhill Biopharma INC. | $46.65 | 2020 | |
| Shionogi INC | $44.18 | 2019 | |
| Ironwood Pharmaceuticals, INC | $29.35 | 2020 | |
| Ardelyx, INC. | $26.33 | 2022 | |
| Qol Medical, LLC | $23.29 | 2021 | |
| Amgen INC. | $20.10 | 2020 | |
| Allergan, INC. | $17.80 | 2019 | |
| Shire North American Group INC | $17.30 | 2019 | |
| Intra-Sana Laboratories | $14.48 | 2022 | |
| Glaxosmithkline, LLC. | $10.93 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subhash Gumber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.